AI Labs
Recursion Pharmaceuticals
A publicly traded 'TechBio' company applying AI foundation models and high-throughput automated labs to drug discovery, which showcased its collaboration with NVIDIA and HighRes Biosolutions on self-driving drug discovery labs at NVIDIA's GTC conference in February 2026. NVIDIA invested $50 million in Recursion in 2023 as part of a strategic collaboration to build BioHive-1-trained AI foundation models for biology and chemistry, though NVIDIA fully exited its equity position in a February 2026 13F filing while the operational partnership continued.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
4 sources · 2 government/SEC filings · 66% avg. source confidence
- U.S. Securities and Exchange Commission (EDGAR) — Recursion Pharmaceuticals, Inc. FY2025 Annual Report (Form 10-K), filed with the SEC95% source confidence
- StocksToTrade — Recursion showcases AI-driven drug discovery with NVIDIA at GTC 202656% source confidence
- CMC Markets — NVIDIA exits Recursion equity stake in February 2026 13F filing despite ongoing partnership54% source confidence
- SEC Form DEF 14A / company disclosures — Recursion cites 'inflection point' with first AI-enabled clinical proof of concept in FAP and fifth Sanofi milestone58% source confidence
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Jul 28, 2026
Dependency Map
What Recursion Pharmaceuticals depends on below, and who depends on Recursion Pharmaceuticals above — click any node to make it the new center, 5 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.